Screener
Veracyte VCYT Business Segments — Compensation expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:LaborAndRelatedExpense.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Allocation of facilities and IT expenses | 1,893 | 2,016 |
| Total research and development | 27,098 | 17,720 |
| Selling and marketing: | ||
| Compensation expense | 19,972 | 17,635 |
| Direct marketing expense | 1,455 | 710 |
| Other selling and marketing expenses (5) | 4,561 | 3,853 |
| Allocation of facilities and IT expenses | 1,168 | 2,256 |
| Total selling and marketing | 27,156 | 24,454 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's business segments — compensation expense?
- Veracyte (VCYT) reported business segments — compensation expense of $19.97M in Q1 2026.
- How has Veracyte's business segments — compensation expense changed year-over-year?
- Veracyte's business segments — compensation expense decreased by 1.0% year-over-year, from $20.17M to $19.97M.
- What is the long-term trend for Veracyte's business segments — compensation expense?
- Over 3 years (2022 to 2025), Veracyte's business segments — compensation expense has grown at a 4.7% compound annual growth rate (CAGR), from $72.26M to $82.91M.
- What does business segments — compensation expense mean?
- Captures the total costs related to employee salaries, benefits, and stock-based compensation specifically attributable to the reportable segment. Monitoring this helps assess the segment's human capital investment and labor cost structure.
Ask your AI about Veracyte's business segments — compensation expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude